Bioengineered Tissues: A Groundbreaking Advancement in Treating Lymphedema
The global rise in cancer cases has resulted in a significant increase in surgeries that often necessitate the removal of lymph nodes. While these surgical interventions are crucial for effectively staging cancer and preventing its spread, they can lead to severe long-term complications. One such consequence is a condition known as secondary lymphedema, which occurs because lymph nodes do not regenerate naturally once they are excised. This debilitating condition manifests as chronic swelling, discomfort, and decreased mobility in the affected areas, ultimately diminishing the quality of life for patients.
In response to this pressing issue, researchers in the field of regenerative medicine are diligently exploring methods to restore or regenerate damaged lymphatic structures to treat secondary lymphedema more effectively. Traditional approaches have primarily focused on utilizing stem cells and lymphatic tissue transplants. Nevertheless, these existing methods often involve complex preparation processes and have shown limited success in alleviating the primary clinical symptoms associated with lymphedema.
Amidst these challenges, a team of researchers led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS) in Japan has made remarkable strides in developing an innovative technique for lymphatic tissue engineering. Their research, detailed in a study published on November 19, 2025, in Volume 16 of Nature Communications (https://www.nature.com/articles/s41467-025-65121-3), outlines a simplified protocol for creating bioengineered lymphatic tissues capable of restoring lymphatic flow following the surgical removal of lymph nodes. This groundbreaking work also included contributions from second-year doctoral student Mr. Shu Obana, Assistant Professor Shoko Itakura, and Professor Makiya Nishikawa, all affiliated with TUS.
This novel methodology is founded on a unique centrifugal cell stacking technique designed to bioengineer replacement tissues for lymph nodes that have been surgically removed. Initially, the researchers introduced mesenchymal stem cells (MSCs), which are recognized for their regenerative properties and ability to provide structural support, into wells of a Transwell culture plate. By centrifuging the entire plate, the MSCs settled uniformly at the bottom, forming the first layer. Next, they added lymphatic endothelial cells and performed another centrifugation cycle, allowing these cells to distribute evenly as a second layer. After a subsequent addition of MSCs followed by a final centrifugation step, the result was a three-layered cellular structure, aptly named centrifuge-based bioengineered lymphatic tissue (CeLyT).
To evaluate the efficacy of this approach, the research team tested the CeLyTs using an animal model of lymphedema. They successfully regenerated functional lymph nodes that bore a structural resemblance to natural lymph nodes. Remarkably, upon transplanting CeLyTs into mice whose popliteal and inguinal lymph nodes had been removed from the right lower limb, lymphatic flow was restored. These mice experienced a significant reduction in lymphedema symptoms, with their paw and leg thickness returning to normal within a few weeks. Additionally, mice receiving CeLyTs demonstrated restored filtration capacity and improved immune cell populations, including T cells and macrophages, along with a reduced accumulation of adipose tissue in the affected regions, achieving levels comparable to healthy mice.
The researchers meticulously examined the structures formed post-CeLyT transplantation to understand the therapeutic effects observed. Dr. Kusamori elaborated, "CeLyTs may initially stimulate the formation of lymph and blood vessels around the transplantation site, resulting in the development of an immature lymph node-like structure by incorporating host-derived cells within several days. This structure then matures to function effectively as a lymph node within ten days post-transplantation."
This research represents the first successful instance of regenerating fully functional lymph nodes through cell transplantation, opening up new, promising avenues for treating patients who develop lymphedema after oncological surgeries involving lymph node dissection. From an economic perspective, a single transplantation could yield enduring therapeutic benefits, significantly lowering the cumulative costs associated with frequent hospital visits and ongoing use of compression garments. Overall, the findings underscore the substantial curative potential of appropriately engineered tissues in the lymphatic system, surpassing the effectiveness of current lymphedema treatment options.
"While compression therapy remains the gold standard for managing lymphedema in clinical practice, it often only delays swelling in affected limbs of lymphedema mice," commented Dr. Kusamori. "In contrast, CeLyTs proved to be more effective in controlling lymphedema, consistently showing strong therapeutic results even in more severe chronic lymphedema models." He added that the effectiveness of CeLyTs surpassed that of other bioengineered tissues created through traditional tissue engineering methods.
Let's keep our fingers crossed for the future clinical application of CeLyTs!
/Public Release. This material originates from the authors and might reflect a specific point in time, having been edited for clarity, style, and length. Mirage.News does not endorse any institutional positions or viewpoints; all opinions, conclusions, and perspectives expressed herein are solely those of the authors. For more details, view the full article here (https://www.miragenews.com/bioengineered-tissue-breakthrough-in-lymphedema-1606974/).
